Driven by science. Defined by excellence.
Leading Innovation in EB Research
Our work is dedicated to advancing scientific understanding and therapeutic innovation for Epidermolysis Bullosa (EB). With over two decades of expertise and commitment to EB research, we contribute to the global effort to improve outcomes for individuals affected by this devastating rare disease.
Through independent projects and strategic collaborations, we address critical challenges in EB by developing and optimizing new treatment and diagnostic approaches. Our integrated activities span the entire research spectrum ā from fundamental and translational R&D and the operation of the EB Biobank to specialized diagnostics and an open innovation platform supporting external partners in EB drug development.
